In my view, Vertex and CRISPR Therapeutics are well-positioned to grab upwards of 20% of Casgevy's total addressable market. The therapy -- a one-time treatment that should provide patients with a functional cure -- costs $2.2 million per treatment in the U.S., so there is a multibillion-dollar opportunity here. Casgevy: The sky is the limit Developing gene-editing therapies is difficult, but commercializing them is its own challenge. To administer Casgevy, physicians first need to collect the patient's cel ...